[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[LLY](/topic/lly)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:lly/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/lly/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% +8%  
**1 Month**: XX% +1%  
**6 Months**: XX% +7%  
**1 Year**: XX% +5%  
**1-Year High**: XXX% on 2025-08-16  
**1-Year Low**: XX% on 2025-04-04  

**Most Supportive Themes**
- **Eli Lilly's Obesity and Diabetes Pipeline:** (45%) Positive sentiment surrounds Eli Lilly's advancements in the obesity and diabetes treatment market, particularly with Mounjaro and Zepbound.
- **TrumpRx and Potential Drug Price Deals:** (30%) News of potential drug price deals with the Trump administration, specifically the TrumpRx platform, is generating positive sentiment for LLY.
- **Positive Analyst Ratings and Growth Projections:** (15%) Many analysts have set high target prices for LLY, with strong growth projections based on the performance of weight management and GLP-1 drugs.
  
**Most Critical Themes**
- **Competition and Market Dynamics:** (5%)  Concerns exist regarding the intensifying competition in the GLP-1 market, particularly from Novo Nordisk (NVO) and potential compounders.
- **Legal and Regulatory Risks:** (5%)  The ongoing lawsuit between LLY and NKTR, along with potential regulatory pressures, poses a risk.
  
Network engagement breakdown:  
| Network | Positive | %   | Neutral | %   | Negative | %   |
| ------- | -------- | -   | ------- | -   | -------- | -   |
| X       | XXXXXX   | XX% | XXXXXXX | XX% | XXXXXX   | X%  |
| TikTok  | XXXXXX   | X%  | XXXXXX  | XX% | XXXXX    | X%  |
| YouTube | XXXXXX   | XX% | XXXXXX  | XX% | XXXXXX   | X%  |
| Reddit  | XX       | X%  | XXX     | X%  | XX       | X%  |
| News    | XX       | X%  | X       | X%  | X        | X%  |
|         |          |     |         |     |          |     |
| Total   | XXXXXXX  | XX% | XXXXXXX | XX% | XXXXXX   | XX% |